Overview

Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation

Status:
Not yet recruiting
Trial end date:
2023-01-26
Target enrollment:
Participant gender:
Summary
The goal of this Phase 2 MCI study is to determine whether 1.0 mg/kg XPro1595 is superior to placebo at improving measures of cognition, functioning and brain quality in individuals with MCI and biomarkers associated with neuroinflammation (APOE4) and to evaluate safety, tolerability, and efficacy of XPro1595.
Phase:
Phase 2
Details
Lead Sponsor:
Inmune Bio, Inc.